trending Market Intelligence /marketintelligence/en/news-insights/trending/Pu9gHuCdmr0wSxWleiSBSw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Health Canada approves CSL unit's hemophilia A treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Health Canada approves CSL unit's hemophilia A treatment

CSL Ltd. unit CSL Behring said Health Canada approved Afstyla for the treatment of hemophilia A.

Afstyla is a novel long-lasting recombinant factor VIII single-chain therapy for adults and children with the congenital bleeding disorder. The approval is based on the results of the Affinity clinical development program.

Afstyla is approved for use in the U.S. and Canada, and is being reviewed by regulators in global markets including the EU, Switzerland and Australia.